Oral Prostacyclin Therapy for PAH: Another Step Forward
Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and cellular proliferation that leads to narrowing and obstruction of small pulmonary arteries. The arteriopathy is clinically manifest as increased pulmonary vascular resistance, and elevation of pulmonary arterial pressures. PAH is considered a progressive vasculopathy that ultimately leads to right heart failure and death. While there is no cure for PAH current pharmacologic therapies have improved morbidity, and in some cases, mortality. The current 3-year survival for patients with PAH managed with state-of-the-art multiple drug therapy remains troubling at approximately 58%.1 This is slightly better than in the 1980's when there were no approved treatments.
- Received December 31, 2012.
- Accepted January 4, 2013.
- Copyright © 2013, Circulation